WO2000040201A3 - Method and means for reducing chemotherapeutic drug resistance in-situ within neoplasms of epithelial cell origin - Google Patents

Method and means for reducing chemotherapeutic drug resistance in-situ within neoplasms of epithelial cell origin Download PDF

Info

Publication number
WO2000040201A3
WO2000040201A3 PCT/US1999/030876 US9930876W WO0040201A3 WO 2000040201 A3 WO2000040201 A3 WO 2000040201A3 US 9930876 W US9930876 W US 9930876W WO 0040201 A3 WO0040201 A3 WO 0040201A3
Authority
WO
WIPO (PCT)
Prior art keywords
situ
epithelial cell
cell origin
drug resistance
neoplasms
Prior art date
Application number
PCT/US1999/030876
Other languages
French (fr)
Other versions
WO2000040201A2 (en
Inventor
Olivier N Kocher
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Priority to AU25940/00A priority Critical patent/AU2594000A/en
Publication of WO2000040201A2 publication Critical patent/WO2000040201A2/en
Publication of WO2000040201A3 publication Critical patent/WO2000040201A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a method and composition means for reducing chemotherapeutic drug resistance exhibited in-situ by a solid mass neoplasm of epithelial cell origin. The tumor cells constituting the solid neoplasm have clinically demonstrated resistance in-situ to a single- or multiple-drug treatment regimen, and the resistant tumor cells express both the PDZK1 protein and the cMOAT protein intracellularly. The invention provides antagonistic antibody preparations which inhibit the interaction of PDZK1 and cMOAT proteins intracellularly; and thereby cause a reduction in clinical resistance to the previously administered chemotherapeutic treatment agents.
PCT/US1999/030876 1998-12-31 1999-12-22 Method and means for reducing chemotherapeutic drug resistance in-situ within neoplasms of epithelial cell origin WO2000040201A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25940/00A AU2594000A (en) 1998-12-31 1999-12-22 Method and means for reducing chemotherapeutic drug resistance in-situ within neoplasms of epithelial cell origin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22462398A 1998-12-31 1998-12-31
US09/224,623 1998-12-31

Publications (2)

Publication Number Publication Date
WO2000040201A2 WO2000040201A2 (en) 2000-07-13
WO2000040201A3 true WO2000040201A3 (en) 2000-09-21

Family

ID=22841463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030876 WO2000040201A2 (en) 1998-12-31 1999-12-22 Method and means for reducing chemotherapeutic drug resistance in-situ within neoplasms of epithelial cell origin

Country Status (2)

Country Link
AU (1) AU2594000A (en)
WO (1) WO2000040201A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5072901B2 (en) * 2003-02-24 2012-11-14 譲治 稲澤 Drug resistance marker and use thereof
US20070148710A1 (en) * 2003-09-12 2007-06-28 Buchsbaum Donald J Cpt resistant cell line

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOOL ET. AL.: "MRP3, An Organic Anion Transporter Able to Transport Anti-cancer Drugs", PROC. NATL. ACAD. SCI. USA., vol. 96, June 1999 (1999-06-01), pages 6914 - 6919, XP002928616 *
NARASAKI ET. AL.: "Human Canalicular Multispecific Organic Anion Transporter (cMOAT) Is Expressed in Human Lung, Gastric, and Colorectal Cancer Cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 240, 1997, pages 606 - 611, XP002928617 *

Also Published As

Publication number Publication date
WO2000040201A2 (en) 2000-07-13
AU2594000A (en) 2000-07-24

Similar Documents

Publication Publication Date Title
EP0679093A1 (en) Methods of delivering agents to target cells.
EP2272859A3 (en) Immunological herpes simplex virus antigens and methods for use thereof
WO2004041153A3 (en) Pharmaceutical composition including low dosages of desmopressin
IL169313A0 (en) Immunotherapy of b cell malignancies and autoimmune disease using nuconjugated antibodies and conjugated antibodies, antibody combinations and fusion proteins
WO2002090566A3 (en) Recombinant tumor specific antibody and use thereof
EE05309B1 (en) β-Am Looid Peptide "Humanized Antibodies, Method for Their Preparation, Their Use, and Pharmaceutical Composition
EP1132097A3 (en) Cellular and serum protein anchors and conjugates
EP0330506A3 (en) Vla proteins
IL105541A0 (en) Monoclonal antibodies to gp130 protein,processes for the preparation thereof and pharmaceutical compositions containing the same
EP0739350A4 (en) Ligand that binds fas antigen
EP1746160A3 (en) Hepatocyte growth factor receptor antagonists and uses thereof
WO1995016038A3 (en) Humanized antibodies and uses thereof
WO1999015553A3 (en) Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
WO1997019111A3 (en) Monoclonal antibodies anti-cd6 and their uses
PT848720E (en) ANTAGONISTS OF ONCOGENIC ACTIVITY OF MDM2 PROTEIN AND ITS USE IN THE TREATMENT OF CANCER
MX2021010531A (en) Bifunctional fusion protein and pharmaceutical use thereof.
EE03287B1 (en) T-cell antigen receptor V region proteins, methods for their preparation, expression vector and bacterial cell for their preparation, pharmaceutical composition containing them, their use in the manufacture of medicaments and diagnostic methods.
WO1991015512A3 (en) Hiv envelope polypeptides
WO1997048804A3 (en) Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses
WO2000040201A3 (en) Method and means for reducing chemotherapeutic drug resistance in-situ within neoplasms of epithelial cell origin
ATE252374T1 (en) ENCAPSULATED ANTIBODY PRODUCING CELLS
BR0214798A (en) Use of anastrozole or a pharmaceutically acceptable salt thereof, and methods for reducing the recurrence rate of cancer and the rate of a new contralateral primary tumor in a postmenopausal woman having early breast cancer.
WO2000061551A3 (en) Pyrimidine-2-one derivatives as integrin receptor ligands
WO2000066173A3 (en) Targeting of infectious agents bearing host cell proteins
AU2001240025A1 (en) Cell cycle proteins associated with rad9, compositions and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase